ACE2 and infection: Using in vitro and in vivo experiments, LL-37 was recently confirmed to suppress SARS-CoV-2 spike pseudovirion infection by binding to SARS-CoV-2 RBD, resulting in competitive ACE-2 recruitment inhibition [19].